200 TGFβ-armoring boosts potency and persistence of engineered TCR T cells, unlocking superior efficacy against HPV-positive solid tumors

MLA

Andreia Costa, et al. “200 TGFβ-Armoring Boosts Potency and Persistence of Engineered TCR T Cells, Unlocking Superior Efficacy against HPV-Positive Solid Tumors.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, Nov. 2021. EBSCOhost, https://doi.org/10.1136/jitc-2021-SITC2021.200.

APA

Andreia Costa, Gail Turner, Gabriela Diaz, Yeonjoo Oh, Jianguo Huang, Jenna Bailey, Cyr De Imus, Stephanie Busch, Teresa Foy, Pallavur Sivakumar, Ruth Salmon, & Cédric Cleyrat. (2021). 200 TGFβ-armoring boosts potency and persistence of engineered TCR T cells, unlocking superior efficacy against HPV-positive solid tumors. Journal for ImmunoTherapy of Cancer, 9(Suppl 2). https://doi.org/10.1136/jitc-2021-SITC2021.200

Chicago

Andreia Costa, Gail Turner, Gabriela Diaz, Yeonjoo Oh, Jianguo Huang, Jenna Bailey, Cyr De Imus, et al. 2021. “200 TGFβ-Armoring Boosts Potency and Persistence of Engineered TCR T Cells, Unlocking Superior Efficacy against HPV-Positive Solid Tumors.” Journal for ImmunoTherapy of Cancer 9 (Suppl 2). doi:10.1136/jitc-2021-SITC2021.200.